Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MYOC | Q99972 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL693976 | 0.94 | HSPB1 (0.55) | HSPB1KMT2AMAPTMEN1NPSR1 | |
| SCHEMBL1242136 | 0.89 | PGR (0.52) | HSPB1KMT2AMAPTMEN1NPSR1 | |
| SCHEMBL24155616 | 0.87 | ALDH1A1 (0.61) | HSPB1KMT2AMAPTMEN1NPSR1 | |
| SCHEMBL10983646 | 0.84 | PGR (0.55) | HSPB1KMT2AMAPTMEN1NPSR1 | |
| SCHEMBL13581180 | 0.84 | MAPT (0.54) | HSPB1KMT2AMAPTMEN1NPSR1 | |
| SCHEMBL11689190 | 0.84 | HSPB1 (0.79) | HSPB1KMT2AMAPTMEN1NPSR1 | |
| 4,4'-Oxybis(Nitrobenzene) SCHEMBL134332 | 0.84 | HSPB1 (0.79) | HSPB1KMT2AMAPTMEN1NPSR1 | |
| SCHEMBL9183872 | 0.84 | HSPB1 (0.79) | HSPB1KMT2AMAPTMEN1NPSR1 | |
| SCHEMBL2011179 | 0.84 | HSPB1 (0.79) | HSPB1KMT2AMAPTMEN1NPSR1 | |
| SCHEMBL1242359 | 0.84 | MEN1 (0.59) | HSPB1KMT2AMAPTMEN1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3293184-B1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA LP (US) | 2020-12-16 | — | — | EP | disclosed |
| US-10196364-B2 | Pyrimidine carboxamides as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2019-02-05 | — | — | US | disclosed |
| EP-2964639-B1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA LP (US) | 2018-05-02 | — | — | EP | disclosed |
| EP-3293184-A1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | Purdue Pharma L.P. (US) | 2018-03-14 | — | — | EP | disclosed |
| US-20170298027-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2017-10-19 | — | — | US | disclosed |
| US-20170298027-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2017-10-19 | — | — | US | disclosed |
| US-20170210713-A1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2017-07-27 | — | — | US | disclosed |
| US-20170210713-A1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2017-07-27 | — | — | US | disclosed |
| EP-2753606-B1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA LP (US) | 2017-07-05 | — | — | EP | disclosed |
| US-9656968-B2 | Pyrimidines as sodium channel blockers | PURDUE PHARMA L.P. | 2017-05-23 | — | — | US | disclosed |
| EP-2072498-A1 | N-PHENYLOXAMIDIC ACID DERIVATIVE | Institute of Medicinal Molecular Design, Inc. (JP) | 2009-06-24 | — | — | EP | disclosed |
| EP-2072498-A1 | N-PHENYLOXAMIDIC ACID DERIVATIVE | Institute of Medicinal Molecular Design, Inc. (JP) | 2009-06-24 | — | — | EP | disclosed |
| US-20080249175-A1 | N-Phenyloxamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-10-09 | — | — | US | disclosed |
| US-20080249175-A1 | N-Phenyloxamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-10-09 | — | — | US | disclosed |
| US-20080249175-A1 | N-Phenyloxamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-10-09 | — | — | US | disclosed |
| US-5382686-A | Process for preparing nitrodiphenyl (thio) ethers | BAYER AKTIENGESELLSCHAFT (DE) | 1995-01-17 | — | — | US | disclosed |
| EP-0304725-B1 | PROCESS FOR THE PREPARATION OF NITRO-DIPHENYL(THIO) ETHERS | BAYER AG (DE) | 1992-01-22 | — | — | EP | disclosed |
| EP-0304725-A1 | Process for the preparation of nitro-diphenyl(thio) ethers | BAYER AG (DE) | 1989-03-01 | — | — | EP | disclosed |
| US-4259532-A | TRIFLUOROMETHOXYHALOPHENOL | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-03-31 | — | — | US | disclosed |
| US-4192669-A | DERIVATIVES OF 2-(4-(4-(TRIFLUOROMETHOXY)-PHENOXY)PHENOXY)AALKANOIC ACIDS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1980-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249175-A1 | N-Phenyloxamide derivatives | SERPINE1, SERPINH1, F12 | HSPB1 1813/4885KMT2A 2850/4885MAPT 4236/4885 |
| US-10196364-B2 | Pyrimidine carboxamides as sodium channel blockers | CACNA1A, TRPV1, TRPA1 | HSPB1 2948/4885KMT2A 2205/4885MAPT 3859/4885 |
| US-20170298027-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | P2RX3, CACNA1A, P2RX4 | HSPB1 2708/4885KMT2A 3494/4885MAPT 3818/4885 |
| US-20170210713-A1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | CACNA1A, TRPV1, TRPA1 | HSPB1 2948/4885KMT2A 2205/4885MAPT 3859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.